/MRNA
MRNA Stock - Moderna, Inc.
Healthcare|BiotechnologyNASDAQ
$33.80+9.21%
+$2.85 (+9.21%) • Dec 19
59
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.88
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).34
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.75
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-7.9%upside
Target: $31.13
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MRNA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$33.46 – $34.14
TARGET (TP)$31.13
STOP LOSS$31.10
RISK/REWARD1:-1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.11
52W High$48.92
52W Low$22.28
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $3.20B | $6.85B | $18.88B | $17.74B | $803.39M |
| Gross Profit | $1.74B | $2.15B | $13.46B | $15.12B | $764.21M |
| Gross Margin | 54.2% | 31.5% | 71.3% | 85.2% | 95.1% |
| Operating Income | $-3,945,000,000 | $-4,239,000,000 | $9.42B | $13.30B | $-763,144,000 |
| Net Income | $-3,561,000,000 | $-4,714,000,000 | $8.36B | $12.20B | $-747,064,000 |
| Net Margin | -111.3% | -68.8% | 44.3% | 68.8% | -93.0% |
| EPS | $-9.27 | $-12.34 | $21.26 | $30.31 | $-1.96 |
Company Overview
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
28%
Hold / Neutral
14
56%
Sell / Underperform
4
16%
Analyst Consensus🔴 Bearish
7 Bullish18 Neutral/Bearish
Price Targets
$100
Average Target
↑ 196.6% Upside
Now
$30
Low
$100
Average
$275
High
Based on 31 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 12th 2025 | Jefferies | Initiation | Hold | $30 |
| March 13th 2025 | Citigroup | Initiation | Neutral | $40 |
| February 18th 2025 | Barclays | Downgrade | Equal Weight | $45← $111 |
| January 29th 2025 | Goldman | Downgrade | Neutral | $51← $99 |
| December 18th 2024 | Argus | Downgrade | Hold | - |
| December 10th 2024 | BofA Securities | Resumed | Underperform | $41 |
| November 19th 2024 | Berenberg | Initiation | Hold | $42 |
| November 18th 2024 | HSBC Securities | Upgrade | Buy | $58 |
| November 15th 2024 | Wolfe Research | Initiation | Underperform | $40 |
| October 17th 2024 | Bernstein | Initiation | Market Perform | $55 |
| September 13th 2024 | Jefferies | Downgrade | Hold | $65← $120 |
| September 13th 2024 | JP Morgan | Downgrade | Underweight | $70← $88 |
| September 13th 2024 | Oppenheimer | Downgrade | Perform | - |
| August 28th 2024 | HSBC Securities | Upgrade | Hold | $82 |
| August 7th 2024 | Deutsche Bank | Upgrade | Hold | $80← $85 |
Earnings History & Surprises
MRNABeat Rate
83%
Last 18 quarters
Avg Surprise
+32.4%
EPS vs Estimate
Beats / Misses
15/3
Last 12 quarters
Latest EPS
$-0.51
Q4 2025
EPS Surprise History
Q1 24
+156.7%
$0.55vs$-0.97
Q2 24
+13.8%
$-3.07vs$-3.56
Q3 24
+0.6%
$-3.33vs$-3.35
Q4 24
+101.6%
$0.03vs$-1.91
Q1 25
+6.7%
$-2.50vs$-2.68
Q2 25
+13.7%
$-2.52vs$-2.92
Q3 25
+28.8%
$-2.13vs$-2.99
Q4 25
+72.7%
$-0.51vs$-1.87
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 13, 2026 | $-2.79 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-1.87 | $-0.51 | +72.7% | ✓ BEAT |
Q3 2025 | Aug 1, 2025 | $-2.99 | $-2.13 | +28.8% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $-2.92 | $-2.52 | +13.7% | ✓ BEAT |
Q1 2025 | Feb 14, 2025 | $-2.68 | $-2.50 | +6.7% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-1.91 | $0.03 | +101.6% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $-3.35 | $-3.33 | +0.6% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $-3.56 | $-3.07 | +13.8% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $-0.97 | $0.55 | +156.7% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-2.01 | $-1.39 | +30.8% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-3.84 | $-3.62 | +5.7% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-1.77 | $0.19 | +110.7% | ✓ BEAT |
Q1 2023 | Feb 23, 2023 | $4.68 | $3.61 | -22.9% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $3.29 | $2.53 | -23.1% | ✗ MISS |
Q3 2022 | Aug 3, 2022 | $4.55 | $5.24 | +15.2% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $5.21 | $8.58 | +64.7% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $9.90 | $11.29 | +14.0% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $9.05 | $7.70 | -14.9% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $5.96 | $6.46 | +8.4% | ✓ BEAT |
Latest News
Moderna shares are trading higher after the company announced that CEPI would invest up to $54.3 million to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure.
📈 PositiveBenzinga•Dec 18, 2025, 07:47 PM
CEPI To Invest Up To $54.3M To Fund Pivotal Phase 3 Trial For Moderna's H5 mRNA Pandemic Influenza Vaccine Candidate mRNA-1018, With 20% Capacity Pledged For LMIC Supply If Licensed
📈 PositiveBenzinga•Dec 18, 2025, 12:06 PM
'FDA Chief Says No Plans To Put Boxed Warning On Covid Vaccines' - Bloomberg News
📈 PositiveBenzinga•Dec 15, 2025, 09:49 PM•Also: , ,
The European Medicines Agency's Committee For Medicinal Products For Human Use Adopted A Positive Opinion Recommending Marketing Authorization Of Moderna's mNEXSPIKE (mRNA-1283), New Covid Vaccine For Individuals Aged 12 Years And Older
📈 PositiveBenzinga•Dec 15, 2025, 12:05 PM
Morgan Stanley Maintains Equal-Weight on Moderna, Lowers Price Target to $28
📉 NegativeBenzinga•Dec 12, 2025, 05:17 PM
ImmunityBio, Novo, Moderna among winners of EU drug recommendations this week
📈 PositiveSeeking Alpha•Dec 12, 2025, 03:45 PM•Also:
Jefferies Initiates Coverage On Moderna with Hold Rating, Announces Price Target of $30
➖ NeutralBenzinga•Dec 12, 2025, 01:26 PM•Also:
Moderna on track to extend gains for the seventh straight trading day
📈 PositiveSeeking Alpha•Dec 11, 2025, 09:03 PM
Nanexa And Moderna Enter Into License And Option Agreement For The Development Of PharmaShell-Based Products; Nanexa To Receive $3M Upfront And Entitled To Up To $500M In Potential Milestone Payments
📈 PositiveBenzinga•Dec 10, 2025, 09:49 PM
Bloomberg: FDA Probes If Covid Shots Might Be Linked to Deaths of Adults
📉 NegativeBenzinga•Dec 9, 2025, 07:13 PM•Also: , ,
Shares of vaccine stocks are trading lower after reports indicating Center for Biologics Evaluation and Research Director Vinay Prasad plans to tighten how vaccines win federal approval, claiming links to child deaths.
📉 NegativeBenzinga•Dec 1, 2025, 04:14 PM•Also: , ,
Piper Sandler Reiterates Overweight on Moderna, Lowers Price Target to $63
➖ NeutralBenzinga•Nov 21, 2025, 05:18 PM
RBC Capital Maintains Sector Perform on Moderna, Lowers Price Target to $25
📉 NegativeBenzinga•Nov 21, 2025, 02:45 PM
Leerink Partners Maintains Underperform on Moderna, Raises Price Target to $18
📉 NegativeBenzinga•Nov 21, 2025, 02:37 PM
Moderna Improves 2026 And 2027 Expected GAAP Operating Expenses By ~$0.5B Each Year On Path To Targeted Cash Breakeven In 2028
📈 PositiveBenzinga•Nov 20, 2025, 12:11 PM
Moderna Expects To Expand Seasonal Vaccine Franchise From Three To Up To Six Approved Products By 2028
📈 PositiveBenzinga•Nov 20, 2025, 12:09 PM
Moderna Announces 3-Yr Business Strategy And Commercial Growth Drivers, Targeting Up To 10% Revenue Growth In 2026
📈 PositiveBenzinga•Nov 20, 2025, 12:08 PM
Moderna Closes 5-Yr Term Loan Facility For Up To $1.5B Of Capital From Ares Management Credit Funds
📈 PositiveBenzinga•Nov 20, 2025, 12:07 PM•Also:
Moderna Expands U.S. Manufacturing Capabilities With Onshoring Of Drug Product Manufacturing To Existing Moderna Technology Center In Norwood, Massachusetts
📈 PositiveBenzinga•Nov 19, 2025, 12:08 PM
B of A Securities Maintains Underperform on Moderna, Lowers Price Target to $21
📉 NegativeBenzinga•Nov 10, 2025, 12:11 PM
Frequently Asked Questions about MRNA
What is MRNA's current stock price?
Moderna, Inc. (MRNA) is currently trading at $33.80 per share. The stock has moved +9.21% today.
What is the analyst price target for MRNA?
The average analyst price target for MRNA is $31.13, based on 1 analyst.
What sector is Moderna, Inc. in?
Moderna, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is MRNA's market cap?
Moderna, Inc. has a market capitalization of $13.20 billion, making it a large-cap company.
Does MRNA pay dividends?
No, Moderna, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBBIO
BridgeBio Pharma, Inc.
$76.30
Mkt Cap: $14.5B
BMRN
BioMarin Pharmaceutical Inc.
$61.15
Mkt Cap: $11.7B
CAI
Caris Life Sciences, Inc.
$27.94
Mkt Cap: $7.9B
EXEL
Exelixis, Inc.
$44.30
Mkt Cap: $11.9B
HALO
Halozyme Therapeutics, Inc.
$67.35
Mkt Cap: $7.9B
JAZZ
Jazz Pharmaceuticals plc
$166.99
Mkt Cap: $10.1B
MDGL
Madrigal Pharmaceuticals, Inc.
$591.02
Mkt Cap: $13.1B
RNA
Avidity Biosciences, Inc.
$72.34
Mkt Cap: $9.5B
RVMD
Revolution Medicines, Inc.
$78.78
Mkt Cap: $15.2B
TECH
Bio-Techne Corporation
$58.27
Mkt Cap: $9.1B
Explore stocks similar to MRNA for comparison